It is also referred to as the third eye (2)
The most recent Phase 3 trial showed discontinuation rates of 12-18% due to adverse events, higher than existing GLP-1 medications
is supported by the NIHR Leicester BRC and has received funding from Astra Zeneca for an investigator-initiated project
Interest in that possibility has grown because addiction, depression, anxiety, and metabolic disease often overlap in the same patients
This is why maintaining hydration and monitoring kidney function regularly is essential when using GLP-1 therapy
Summary: Ozempic can cause light-headedness in fewer than 1 in 100 patients, typically through indirect mechanisms such as hypoglycaemia, dehydration, or blood pressure changes rather than direct pharmacological effects